|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
"You Think It Won't Happen to You" — Teddi Mellencamp on Melanoma and Speaking Up
2
A CAR-T Therapy Is Working Better Than Expected for Patients With Hard to Treat Leukemia
3
Bridging the Gap for Latina Breast Cancer Survivors
4
Your Tumor's Genetic Profile May Not Change Which Treatment Works Best for TNBC
5